heart disease news from FierceBiotech
NewsALSO NOTED: Researchers testing stem cell therapy for CHF; Boehringer unveils new research center; and much more...
> Fifty-six of the nation's most creative biomedical scientists are being given the opportunity to tackle their most ambitious, risky research plans, as they become the newest class of Howard Read more...
FDA's delay of Geron ESC trial raises concerns
Getting an embryonic stem cell therapy through clinical trials in the U.S. is looking like an increasingly tough challenge after Geron announced that the FDA is delaying a study of its experimental Read more...
BMS inks $227M collaboration deal with KAI
South San Francisco-based KAI Pharmaceuticals is getting a $25 million boost from Bristol-Myers Squibb---its upfront payment for a collaboration on KAI-9803, an experimental therapy to reduce the Read more...
Cholesterol drug delay signals new FDA standards
In what may signal a major shift in FDA standards, Isis and Genzyme say that they expect to add another year to the development timeline for a closely watched cholesterol therapy in order to produce Read more...
Genzyme gets biosimilar rejection, builds R&D plant
The FDA have given a thumbs down to Genzyme's request for permission to sell its Pompe disease drug Read more...
Trial delay forces Vasogen to hack 85% of staff
Hit by a clinical trial delay triggered by a surprise change-up at the FDA, Canada's Vasogen has hit the brakes on spending and announced plans to lay off 85 percent of its work force. The Canadian Read more...
ALSO NOTED: PDL offers bonuses to top execs; Radius earns $28.3M for milestone;Cytokinetics surges on positive data; and much m
> PDL BioPharma says it will pay four top executives nearly $1 million in bonuses through the end of next year to keep them on board as the company undergoes a transformation into an antibody Read more...
Clinical trial data disappears in NIH laptop heist
After waiting for nearly a month, officials at the National Institutes of Health alerted some 2,500 people that their names, addresses and detailed personal health information gathered from heart Read more...
SPOTLIGHT: Stem cell trial approved
Osiris Therapeutics has been given a green light by the FDA to start a Phase II trial of Prochymal--a formulation of adult stem cells--for heart attack victims. Read more...
ALSO NOTED: ZymoGenetics to chop jobs; Evotec extends collaboration; Iomai touts results for vaccine patch; and much more...
> ZymoGenetics is chopping 80 jobs--mostly in R&D--after facing some tough reviews for the potential of its newly released drug Recothrom--a genetically engineered form of thrombin to prevent Read more...
| Press ReleasesPRESS RELEASE: UF researchers test stem cell therapy for heart patients UF researchers test stem cell therapy for heart patients GAINESVILLE, Fla. — University of Florida doctors on Wednesday treated their first patient enrolled in a new study designed to test Read more... PRESS RELEASE: Stem Cells Improve Heart Function After Heart Attack GERON SCIENTISTS AND COLLABORATORS DEMONSTRATE HUMAN EMBRYONIC STEM CELL-DERIVED CARDIOMYOCYTES IMPROVE HEART FUNCTION WHEN TRANSPLANTED AFTER MYOCARDIAL INFARCTION Landmark Read more... |
Get more heart disease coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends